Navigation Links
Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
Date:2/28/2008

n the United States. Imiquimod and other TLR7 agonists have also demonstrated early clinical activity against other tumor types, including melanoma and chronic lymphocytic leukemia.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the planned scope and trial design of the ANA773 clinical trial, the belief that ANA773 holds promise for the treatment of a range of malignancies, and that it may have utility when combined with targeted agents, therapeutic antibodies and/or chemotherapy, Anadys' ability to identify a dose and schedule for Phase II investigation by the end of this year and the ability to develop ANA773 as a therapy for patients with cancer. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, di
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
7. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
8. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
11. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... of rod-shaped metal nanoparticles in water with ultrasound and ... bits. Why? No one yet knows exactly. But researchers ... have clocked their speedand it,s fast. At up to ... faster than any nanoscale object submerged in liquid ever ... opened up the possibility that they could be used ...
(Date:7/22/2014)... 2014   BioTE Medical , a leading ... hormone pellets, today announced the addition of Dr. ... Dr. Rouzier is joining the BioTE Medical Advisory ... Dr. Rouzier was residency trained in Family Medicine ... board certified emergency physician still practicing at a ...
(Date:7/22/2014)... CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and distributor ... other markets, announced today that it has closed on ... investors led by Novit L.P., an investment arm of ... the signing of a Securities Purchase Agreement under which ... a price per share of $1.00, resulting in a ...
(Date:7/22/2014)... 2014 Rice Lake Weighing ... 2014 NCSL International Workshop and Symposium July 28-31 ... CONDEC pressure instrumentation, OIML M1 weights, precision lab ... customized sets, Essential Weights™. , NCSL International was ... in solving the common problems faced by measurement ...
Breaking Biology Technology:NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2
... (Nasdaq: EXEL ) announced today that George A. ... present at the Goldman Sachs,29th Annual Global Healthcare Conference ... 2008. Dr. Scangos will discuss updates to the company,s,development ... webcast and may be accessed in the Event,Calendar page ...
... - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ... today announced the completion of U.S. clinical,trial enrolment ... "Our proprietary Bio-Seal product represents a potentially ... cancer," said Dr.,William Hunter, President and CEO of ...
... Corporation and,ATEL Ventures, Inc., today announced they have ... a privately held, venture-backed life,science company., AxoGen ... nerve repair. Their,patented product, AVANCE(TM) Nerve Graft is ... and regeneration of peripheral nerves., "Oxford,s and ...
Cached Biology Technology:Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 2Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 3Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 4Oxford Finance Corporation and ATEL Ventures, Inc. Provide $7.5 Million Venture Loan to AxoGen, Inc. 2
(Date:7/22/2014)... New research from the Monell Center reveals that simply ... airway inflammation in asthmatics for at least 24 hours ... can play in health-related outcomes. , "Asthmatics often are ... an odor is harmful, our bodies react as if ... Cristina Jan, PhD, a Monell physiologist. "Both patients and ...
(Date:7/22/2014)... 2014, by lightning from a weather system that moved through ... Stokes Fire, Gold Hikes Fire, French Creek Fire and the ... one larger fire. The fires are burning in timber and ... in size. The present fire situation continues to rapidly ... safety is the priority on the Carlton Complex fires. ...
(Date:7/22/2014)... Health Policy and Economics have linked tighter Medicaid ... for schizophrenic individuals. , The study comes amid ... actually save money, when other costs are taken ... extra approval step before tests or treatments can ... prior authorization is intended to encourage physicians ...
Breaking Biology News(10 mins):In asthma, it's not just what you smell, but what you think you smell 2In asthma, it's not just what you smell, but what you think you smell 3Are state Medicaid policies sentencing people with mental illnesses to prison? 2
... designed to block cat allergies successfully prevented allergic reactions ... in a test tube, University of California, Los Angeles ... Medicine, available online now. In the future, the investigators ... therapy not only for human cat allergies, but also ...
... scientists have found,that bacteria can use a Sonar-like ... or other bacteria) and target them for destruction.,Reported ... finding explains how,some bacteria know when to produce ... lead to the design of new toxin inhibitors. ...
... Patent # 6,872,552, "A Method of Reconstituting Nucleic Acid ... MatrixDesign, and CEO of DermaPlus, Inc. The patent covers ... samples, and could allow scientists to reassemble everything from ... discovery, when properly applied by our scientists, brings us ...
Cached Biology News:Novel Therapy Tested in Mice Could Chase Away Cat Allergies 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 3Antibiotic Resistant Bacterium Uses Sonar-like Strategy to “See?Enemies or Prey 2Dinosaur DNA? New Patent Covers Degraded DNA recovery 2
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Eppendorf tube holder, for Tube rack 175 x 12 mm, 100. Category: Chromatography Systems & Accessories, Systems....
Pooled normal sreum with 0.1% sodium azide as preservative...
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: